Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $32.9 million.

  • Arrowhead Pharmaceuticals' Accounts Payables rose 12782.74% to $32.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.9 million, marking a year-over-year increase of 12782.74%. This contributed to the annual value of $17.7 million for FY2025, which is 5519.85% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Accounts Payables of $32.9 million as of Q4 2025, which was up 12782.74% from $17.7 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Accounts Payables' 5-year high stood at $35.9 million during Q3 2023, with a 5-year trough of $796000.0 in Q4 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Accounts Payables value was $9.8 million (recorded in 2023), while the average stood at $13.1 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 8043.26% in 2022, then skyrocketed by 115055.79% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Accounts Payables (Quarter) stood at $4.1 million in 2021, then crashed by 80.43% to $796000.0 in 2022, then surged by 460.3% to $4.5 million in 2023, then surged by 224.15% to $14.5 million in 2024, then soared by 127.83% to $32.9 million in 2025.
  • Its Accounts Payables was $32.9 million in Q4 2025, compared to $17.7 million in Q3 2025 and $33.0 million in Q2 2025.